These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27513253)

  • 21. Longitudinal Change of Refractive Error in Retinopathy of Prematurity Treated With Intravitreal Bevacizumab or Laser Photocoagulation.
    Wiecek E; Akula JD; Vanderveen DK; Mantagos IS; Wu C; Curran AL; De Bruyn H; Peterson B; Fulton AB
    Am J Ophthalmol; 2022 Aug; 240():252-259. PubMed ID: 35367438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
    Toy BC; Schachar IH; Tan GS; Moshfeghi DM
    Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
    Harder BC; von Baltz S; Jonas JB; Schlichtenbrede FC
    Acta Ophthalmol; 2014 Sep; 92(6):577-81. PubMed ID: 24020921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.
    Lepore D; Quinn GE; Molle F; Orazi L; Baldascino A; Ji MH; Sammartino M; Sbaraglia F; Ricci D; Mercuri E
    Ophthalmology; 2018 Feb; 125(2):218-226. PubMed ID: 28867130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Refractive Trend of Stage 3 Retinopathy of Prematurity.
    Padidam S; Le K; Lin X
    J Pediatr Ophthalmol Strabismus; 2018 Nov; 55(6):403-406. PubMed ID: 30452767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.
    Parchand SM; Agrawal D; Gangwe A; Saraogi T; Agrawal D
    Indian J Ophthalmol; 2021 Aug; 69(8):2164-2170. PubMed ID: 34304202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP).
    Etezad Razavi M; Shoeibi N; Hassanzadeh S; Kianmehr S; Bakhtiari E
    Strabismus; 2020 Mar; 28(1):49-54. PubMed ID: 31790628
    [No Abstract]   [Full Text] [Related]  

  • 28. Retinopathy of prematurity in infants weighing less than 500 grams at birth enrolled in the early treatment for retinopathy of prematurity study.
    Wheeler DT; Dobson V; Chiang MF; Bremer DL; Gewolb IH; Phelps DL; Hardy RJ; Good WV; Fellows R; Tung BP; Palmer EA
    Ophthalmology; 2011 Jun; 118(6):1145-51. PubMed ID: 21211840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants.
    Yi Z; Su Y; Zhou Y; Zheng H; Ye M; Xu Y; Chen C
    Curr Eye Res; 2016 Aug; 41(8):1092-1097. PubMed ID: 26580816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy.
    Chan JJT; Lam CPS; Kwok MKM; Wong RLM; Lee GKY; Lau WWY; Yam JCS
    Sci Rep; 2016 Jun; 6():27082. PubMed ID: 27256987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.
    Chung EJ; Kim JH; Ahn HS; Koh HJ
    Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1727-30. PubMed ID: 17690897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression.
    Vural A; Ekinci DY; Onur IU; Hergünsel GO; Yiğit FU
    Int Ophthalmol; 2019 Oct; 39(10):2267-2274. PubMed ID: 30604251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity.
    Murakami T; Sugiura Y; Okamoto F; Okamoto Y; Kato A; Hoshi S; Nagafuji M; Miyazono Y; Oshika T
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2849-2855. PubMed ID: 33744981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.
    Freedman SF; Hercinovic A; Wallace DK; Kraker RT; Li Z; Bhatt AR; Boente CS; Crouch ER; Hubbard GB; Rogers DL; VanderVeen D; Yang MB; Cheung NL; Cotter SA; Holmes JM;
    Ophthalmology; 2022 Oct; 129(10):1120-1128. PubMed ID: 35660415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series.
    Roohipoor R; Ghasemi H; Ghassemi F; Karkhaneh R; Riazi-Esfahani M; Nili-Ahmadabadi M
    Graefes Arch Clin Exp Ophthalmol; 2011 Sep; 249(9):1295-301. PubMed ID: 21494873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RETINAL VASCULAR DEVELOPMENT WITH 0.312 MG INTRAVITREAL BEVACIZUMAB TO TREAT SEVERE POSTERIOR RETINOPATHY OF PREMATURITY: A Longitudinal Fluorescein Angiographic Study.
    Lorenz B; Stieger K; Jäger M; Mais C; Stieger S; Andrassi-Darida M
    Retina; 2017 Jan; 37(1):97-111. PubMed ID: 27454223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Refractive Errors and Ocular Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity.
    Gunay M; Sekeroglu MA; Bardak H; Celik G; Esenulku CM; Hekimoglu E; Bardak Y
    Strabismus; 2016 Jun; 24(2):84-8. PubMed ID: 27120579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity.
    Eftekhari Milani A; Hassanpoor N; Mousavi Mirkala M; Taheri A; Golizade A; Niyousha MR
    Int Ophthalmol; 2020 Feb; 40(2):477-482. PubMed ID: 31712928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
    Kang HG; Kim TY; Han J; Han SH
    Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity?
    Spandau U; Tomic Z; Ewald U; Larsson E; Akerblom H; Holmström G
    Acta Ophthalmol; 2013 Mar; 91(2):170-5. PubMed ID: 22268644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.